Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2018

01-06-2018 | Correction

Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC)

Authors: A. Barnadas, M. Algara, O. Cordoba, A. Casas, M. Gonzalez, M. Marzo, A. Montero, M. Muñoz, A. Ruiz, F. Santolaya, T. Fernandez

Published in: Clinical and Translational Oncology | Issue 6/2018

Login to get access

Excerpt

In the original article the affiliation of a scientific society involved in the consensus was displayed incorrectly. Thus, currently SEMERGEN appears in the paper as “Spanish Society of General Medicine” or “(1) Sociedas Española de Medicina General”. The correct denomination of the Society is “Spanish Society of Primary Care Physicians” or “Sociedad Española de Médicos de Atención Primaria”. …
Metadata
Title
Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of
Authors
A. Barnadas
M. Algara
O. Cordoba
A. Casas
M. Gonzalez
M. Marzo
A. Montero
M. Muñoz
A. Ruiz
F. Santolaya
T. Fernandez
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1822-z

Other articles of this Issue 6/2018

Clinical and Translational Oncology 6/2018 Go to the issue

Research Article

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

Research Article

Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma

Special Article

Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC)

Review Article

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223

Research Article

Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study

Research Article

MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits